Engineered T-Cell Therapy

Engineered T cells are the result of turning a therapeutic process into a product capable of overcoming checkpoint inhibition, and are the future of adoptive immunotherapy. Cytokine release syndrome,” a storm of molecules generated as the cells fights the cancer. Instead of an antibody, single-chain target domain, he used a human cytokine, IL-13, with a mutation in the sequence that gave high affinity for IL-13 receptor α2. These cells were infused intra cranially, establishing the safety of intracranial administration with some antitumor responses.

  • CAR Strategies in Solid Tumours
  • Prolongation of T-Cell Response by OX40 CC-Signaling CARS
  • Proffered Paper: A New PD-1-CD28 Chimeric Receptor Overcomes PD1-Mediated Immune Suppression in Adoptive T-Cell Therapy
  • Proffered Paper: In-Vivo Testing of PSMA-Targeted T-Cell Immunotherapy for Prostate Cancer

Related Conference of Engineered T-Cell Therapy

April 04-05, 2024

38th International Conference on Immunology

Madrid, Spain
May 23-24, 2024

18th International Conference on European Immunology

Zurich, Switzerland

Engineered T-Cell Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in